Compare SN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SN | BBIO |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 15.3B |
| IPO Year | 2023 | 2019 |
| Metric | SN | BBIO |
|---|---|---|
| Price | $97.45 | $68.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 25 |
| Target Price | ★ $132.88 | $83.96 |
| AVG Volume (30 Days) | 1.7M | ★ 2.2M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 4.94 | N/A |
| Revenue | ★ $6,399,188,000.00 | $502,076,000.00 |
| Revenue This Year | $15.20 | $88.16 |
| Revenue Next Year | $10.74 | $74.13 |
| P/E Ratio | $20.64 | ★ N/A |
| Revenue Growth | 15.75 | ★ 126.26 |
| 52 Week Low | $60.50 | $28.33 |
| 52 Week High | $133.99 | $84.94 |
| Indicator | SN | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 29.24 | 46.80 |
| Support Level | $88.92 | $61.95 |
| Resistance Level | $100.05 | $68.71 |
| Average True Range (ATR) | 4.28 | 2.86 |
| MACD | -1.46 | 0.43 |
| Stochastic Oscillator | 3.58 | 43.93 |
SharkNinja Inc is a product design and technology company that creates 5-star-rated lifestyle solutions through inventive products for consumers around the world. Its product categories include Cleaning, Cooking, Food Preparation, Home Environment and Beauty products. It sells vacuum cleaners, cooking pots, fryers, hair dryers, etc. The SharkNinja Group is expected to carry on the design, production, marketing, and distribution of the Shark and Ninja brands of small household appliances in North America, Europe and other selected international markets (excluding the Asia Pacific Region and Greater China). Currently, the majority of the revenue is derived from the U.S. market.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.